Best Practices for ME/CFS Clinical Trials
- Aug 26, 2025
- 6 min read
Updated: 5 days ago
Field Guide for Research Teams and Patient-Centered Organizations
This paper is part of the CYNAERA ME/CFS Library, a growing resource for post-exertional malaise, pacing, and remission for myalgic encephalomyelitis/chronic fatigue syndrome.
By Cynthia Adinig
1. Frame the Study Around Stabilization, Not Just Cure
ME/CFS is a relapsing, multisystem condition characterized by immune disruption, neuroinflammation, autonomic dysfunction, and energy metabolism abnormalities (Institute of Medicine, 2015; Komaroff, 2021). Trials should anchor in stabilization before pursuing cure.
Define remission with patient-centered outcomes: return to baseline function, reduction in crashes, or sustainable pacing (Davenport et al., 2019).
Prioritize stabilization as a first-phase outcome to prevent participant harm (Bateman et al., 2021).
2. Prioritize Deep Screening for Comorbid Conditions
Participants should be screened and stratified for:
POTS / dysautonomia (Rowe et al., 2014)
Mast Cell Activation Syndrome (MCAS) (Afrin et al., 2017)
Autoimmune/connective tissue disorders such as EDS (Castori et al., 2017)
Endocrine instability (HPA axis, thyroid, sex hormones) (Natelson et al., 2017)
Pediatric onset and trauma history (Jason et al., 2006)
Inclusion/exclusion criteria should reflect known overlap and avoid ignoring fragile or complex patients.
3. Design a Multi-Stage, Adaptive Trial Architecture
Stage 1: Stabilization
Gentle interventions: electrolytes, antihistamines, pacing education, environmental control (Bateman et al., 2021).
Allow washout/onboarding periods to confirm baseline.
Stage 2: Targeted Therapeutics
Agents for mitochondrial, antiviral, neuroinflammatory, or autonomic dysfunction (Cook et al., 2017).
Biomarker-adaptive arms using immune or neuro profiles (Hornig et al., 2015).
Stage 3: Maintenance & Flare Prevention
Track relapse triggers (Meeus et al., 2012).
Use platform designs with flexible stopping rules (FDA, 2022).
4. Use Endpoints That Reflect Real-World Terrain
Primary endpoints
Sustained remission or stability (3–6 months) (Institute of Medicine, 2015)
Composite Digital Health Score: cognition, HRV, sleep (Kogelnik et al., 2020)
Reduction in PEM frequency/duration (Davenport et al., 2019)
Secondary endpoints
Hospital avoidance, crash severity
Autonomic metrics (Rowe et al., 2014)
Functionality restoration (Bateman et al., 2021)
5. Integrate AI and Digital Biomarkers
Use wearable tech and dashboards to capture flare onset (Kogelnik et al., 2020).
Integrate terrain-based symptom tracking (heat sensitivity, barometric reactivity).
Employ adaptive learning algorithms to map early-warning PEM indicators (CYNAERA, 2025).
6. Use Simulation Modeling Before Launch
Run digital trial simulations (e.g., CYNAERA Clinical Trials Simulator™)
Model participant dropouts, flare events, placebo sensitivity (Ioannidis, 2016).
Adjust trial arms and eligibility based on modeled outcomes.
7. Engage Ethical Oversight with Patient Representation
Include ME/CFS patient advocates in DSMB design (NIH CDE Working Group, 2019).
Use tiered informed consent for experimental interventions (FDA, 2022).
Allow participants to pause or revert protocol steps if destabilized.
8. Plan for Uptake and Licensing Across Borders
Provide open-access stabilization protocols and digital symptom trackers.
Design modular diagnostics for primary care.
Offer licensing for pharma partners with clear community benefit clauses (FDA, 2022).
9. Document, Share, and Future-Proof Your Work
Publish both negative and positive findings (Ioannidis, 2016).
Maintain a “Why It Works” rationale for every intervention.
Enable remixing by other researchers and organizations.
Summary
ME/CFS trials succeed when they prioritize stabilization, validate comorbid complexity, and use flexible, adaptive designs. The CYNAERA approach embeds digital biomarkers, simulation modeling, and patient-centered endpoints to reduce trial failure and increase reproducibility. These gaps are further explored through The Eve Research Project, an ongoing research program capturing real-world patient data across hormonal life stage, immune activity, and environmental exposure. The findings highlight how current clinical trials often fail to account for variability in disease expression, leading to inconsistent outcomes across key patient populations.
CYNAERA Framework Papers and Core Research Libraries
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press, 2015.
Komaroff, A.L. (2021). "Advances in understanding the pathophysiology of ME/CFS." Nature Reviews Disease Primers, 7(1), 68.
Davenport, T.E., Stevens, S.R., VanNess, J.M., Stevens, J. (2019). "Conceptual Model for Post-Exertional Malaise in ME/CFS." Fatigue: Biomedicine, Health & Behavior.
Rowe, P.C., Barron, D.F., Calkins, H., et al. (2014). "Orthostatic intolerance and CFS." Journal of Pediatrics.
Afrin, L.B., et al. (2017). Mast Cell Activation Syndrome and Related Disorders. Springer.
Castori, M., et al. (2017). "EDS and comorbidities in CFS." Clinical and Experimental Rheumatology.
Natelson, B.H., et al. (2017). "Endocrine abnormalities in ME/CFS." Endocrine Reviews.
Jason, L.A., et al. (2006). "Childhood trauma and CFS onset." Journal of Chronic Fatigue Syndrome.
Bateman, L., Rowe, P.C., & Montoya, J.G. (2021). "Post-exertional malaise in ME/CFS." Frontiers in Pediatrics.
Cook, D.B., Light, A.R., et al. (2017). "Neuroinflammatory markers in ME/CFS." Brain, Behavior, and Immunity.
Hornig, M., Montoya, J.G., Klimas, N., et al. (2015). "Distinct plasma immune signatures in ME/CFS." Science Advances, 1(1), e1400121.
Meeus, M., et al. (2012). "PEM and exercise intolerance." Clinical Rheumatology.
Kogelnik, A.M., et al. (2020). "Digital tools for ME/CFS research." JMIR Formative Research.
CYNAERA. Comprehensive MECFS Overview White Paper, 2025
NIH. Common Data Elements Working Group: ME/CFS Recommendations. 2019.
FDA. Guidance on Decentralized Clinical Trials. 2022.
Ioannidis, J.P.A. (2016). "Reproducibility in research." JAMA.
Comments